Development of a Freeze-Stable Formulation for Vaccines Containing Aluminum Salt Adjuvants

This article, published in Vaccine, describes an approach to minimize reliance on the proper implementation of the cold chain to protect vaccines from freeze-thaw inactivation. By including PEG 300, propylene glycol, or glycerol in a hepatitis B vaccine, particle agglomeration, changes in the fluorescence emission spectrum--indicative of antigen tertiary structural changes--and losses of in vitro and in vivo indicators of potency were prevented following multiple exposures to -20°C. The effect of propylene glycol was examined in more detail and revealed that even at concentrations too low to prevent freezing at -10°C, -20°C, and -80°C, damage to the vaccine could be prevented. The journal may be accessed at http://www.sciencedirect.com/science/journal/0264410X. Copyright Elsevier (2009).

Author(s): Jones Braun L, Tyagi A, Perkins S, et al.

Published: 2009

  • Download file (English)

    519 KB PDF

    Citation: Jones Braun L, Tyagi A, Perkins S, et al. Development of a Freeze-Stable Formulation for Vaccines Containing Aluminum Salt Adjuvants. Vaccine. 2009;27(1):72-79.

Resource types: Peer-reviewed journal

Diseases: Hepatitis B

Topics: Vaccine stabilization

Regions: Global